EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Retatrutide—A Game Changer in Obesity Pharmacotherapy

Vasiliki Katsi, Georgios Koutsopoulos iD, Christos Fragoulis iD, Kyriakos Dimitriadis, Konstantinos Tsioufis iD

Biomolecules · 30.05.2025 · 15 (6) · 796

DOI: 10.3390/biom15060796 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 30.05.2025. Verfasst von Vasiliki Katsi und 4 weiteren Autor:innen. Beteiligte Einrichtung: 1st Cardiology Clinic, National & Kapodistrian University of Athens, 11527 Athens, Greece. Hauptthemen laut MEDLINE: Obesity, Diabetes Mellitus, Type 2, Anti-Obesity Agents. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Obesity and type 2 diabetes mellitus (T2DM) are global health crises with significant morbidity and mortality. Retatrutide, a novel triple receptor agonist targeting glucagon-like peptide-1 (GLP-1), Glucose-Dependent Insulinotropic Polypeptide (GIP), and glucagon receptors, represents a groundbreaking advancement in obesity and T2DM pharmacotherapy. This review synthesizes findings from preclinical and clinical studies, highlighting retatrutide’s mechanisms, efficacy, and safety profile. Retatrutide’s unique molecular structure enables potent activation of GLP-1, GIP, and glucagon receptors, leading to significant weight reduction, improved glycemic control, and favorable metabolic outcomes. Animal studies demonstrate retatrutide’s ability to delay gastric emptying, reduce food intake, and promote weight loss, with superior efficacy compared to other incretin-based therapies. Phase I and II clinical trials corroborate these findings, showing dose-dependent weight loss, reductions in Glycated Hemoglobin (HbA1c) levels, and improvements in liver steatosis and diabetic kidney disease. Common adverse effects are primarily gastrointestinal and dose-related. Ongoing Phase III trials, such as the TRIUMPH studies, aim to further evaluate retatrutide’s long-term safety and efficacy in diverse patient populations. While retatrutide shows immense promise, considerations regarding cost and the quality of weight loss beyond BMI reduction warrant further investigation. Retatrutide heralds a new era in obesity and T2DM treatment, offering hope for improved patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ObesityDiabetes Mellitus, Type 2Anti-Obesity AgentsHumansAnimalsGastric Inhibitory PolypeptideGlucagon-Like Peptide 1Receptors, GlucagonWeight LossFatty AcidsPeptides

Stichwörter der Autor:innen

incretinsobesityretatrutidetype 2 diabetes mellitus

Substanzen

Gastric Inhibitory PolypeptideGlucagon-Like Peptide 1Anti-Obesity AgentsReceptors, GlucagonretatrutideFatty AcidsPeptides

Autor:innen und Institutionen

  • 1st Cardiology Clinic, National & Kapodistrian University of Athens, 11527 Athens, Greece.

ORCID-Profile: Georgios Koutsopoulos, Christos Fragoulis, Konstantinos Tsioufis

Zitieren

APA

Katsi, V., Koutsopoulos, G., Fragoulis, C., Dimitriadis, K., & Tsioufis, K. (2025). Retatrutide—A Game Changer in Obesity Pharmacotherapy. Biomolecules, 15(6), 796. https://doi.org/10.3390/biom15060796

Vancouver

Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Retatrutide—A Game Changer in Obesity Pharmacotherapy. Biomolecules. 2025;15(6):796. doi:10.3390/biom15060796

BibTeX
@article{Katsi2025,
  author = {Katsi, Vasiliki and Koutsopoulos, Georgios and Fragoulis, Christos and Dimitriadis, Kyriakos and Tsioufis, Konstantinos},
  title = {Retatrutide—A Game Changer in Obesity Pharmacotherapy},
  journal = {Biomolecules},
  year = {2025},
  volume = {15},
  number = {6},
  pages = {796},
  doi = {10.3390/biom15060796}
}
Kostenlos starten →